MA45011A - Composé thérapeutique contre la douleur et sa synthèse - Google Patents

Composé thérapeutique contre la douleur et sa synthèse

Info

Publication number
MA45011A
MA45011A MA045011A MA45011A MA45011A MA 45011 A MA45011 A MA 45011A MA 045011 A MA045011 A MA 045011A MA 45011 A MA45011 A MA 45011A MA 45011 A MA45011 A MA 45011A
Authority
MA
Morocco
Prior art keywords
synthesis
therapeutic compound
compound against
against pain
pain
Prior art date
Application number
MA045011A
Other languages
English (en)
French (fr)
Inventor
Bart Lieven Daniel Decorte
Menno Cornelis Franciscus Monnee
Jacob Cornelis Russcher
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA45011A publication Critical patent/MA45011A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
MA045011A 2015-09-04 2016-09-01 Composé thérapeutique contre la douleur et sa synthèse MA45011A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562214734P 2015-09-04 2015-09-04
US201562214727P 2015-09-04 2015-09-04

Publications (1)

Publication Number Publication Date
MA45011A true MA45011A (fr) 2021-06-02

Family

ID=58188341

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045011A MA45011A (fr) 2015-09-04 2016-09-01 Composé thérapeutique contre la douleur et sa synthèse

Country Status (11)

Country Link
US (9) US10040797B2 (enExample)
EP (5) EP3344627B9 (enExample)
JP (5) JP6868008B2 (enExample)
CN (5) CN109153679B (enExample)
CA (5) CA2997541C (enExample)
DK (4) DK3344627T5 (enExample)
ES (4) ES2807901T3 (enExample)
IL (5) IL257732B (enExample)
MA (1) MA45011A (enExample)
TW (11) TWI639597B (enExample)
WO (5) WO2017040767A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2997541C (en) * 2015-09-04 2022-01-11 Janssen Pharmaceutica Nv Therapeutic compounds for pain and synthesis thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1469781A (en) * 1974-06-10 1977-04-06 Boehringer Sohn Ingelheim Production of scopine
US4232026A (en) * 1978-07-20 1980-11-04 Merck & Co., Inc. Diazaditwistanes, and pharmaceutical compositions for treating pain in warm blooded animals containing them
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE69106365T2 (de) * 1990-07-23 1995-05-04 Pfizer Chinuclidinderivate.
WO1992006188A2 (en) 1990-10-05 1992-04-16 Barnes Wayne M Thermostable dna polymerase
US6432976B1 (en) * 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
DE10050994A1 (de) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
ES2329133T3 (es) * 2003-05-28 2009-11-23 Theravance, Inc. Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos.
CA2539811A1 (en) * 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
US7732607B2 (en) * 2005-08-22 2010-06-08 Anatoly Mazurov Heteroaryl-substituted diazatricycloalkanes and methods of use thereof
US8735411B2 (en) * 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
WO2008104955A1 (en) * 2007-02-28 2008-09-04 Ranbaxy Laboratories Limited Azoniatricyclo [3.3.1.0] nonane derivatives as muscarinic receptor antagonists
TW200840569A (en) * 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
WO2009124755A1 (en) * 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
CN101768158B (zh) * 2010-01-04 2013-05-29 南昌弘益科技有限公司 噻托溴铵无水物及其制备方法
CN102579458A (zh) * 2012-03-08 2012-07-18 冀中能源峰峰集团有限公司总医院 缓解静点药物所致疼痛和防治静脉炎的药品配方
JP6102122B2 (ja) * 2012-08-24 2017-03-29 ソニー株式会社 画像処理装置および方法、並びにプログラム
EP2897948B1 (en) * 2012-09-18 2016-08-31 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists
TW201444849A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
JO3509B1 (ar) * 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
KR20160115503A (ko) * 2015-03-27 2016-10-06 차의과학대학교 산학협력단 만성 골수성 백혈병 암 줄기세포의 성장 또는 증식 억제용 조성물 및 이의 스크리닝 방법
GB201505654D0 (en) * 2015-04-01 2015-05-13 Nordic Bioscience As Immunoassay for collagen type VI sequence
GB201505701D0 (en) * 2015-04-02 2015-05-20 Byotrol Plc Anti-microbial composition
CA2997541C (en) * 2015-09-04 2022-01-11 Janssen Pharmaceutica Nv Therapeutic compounds for pain and synthesis thereof

Also Published As

Publication number Publication date
TWI713879B (zh) 2020-12-21
DK3344626T5 (da) 2021-09-06
CN109071540A (zh) 2018-12-21
CA2997501C (en) 2022-05-10
TWI683815B (zh) 2020-02-01
ES2808048T3 (es) 2021-02-25
EP3344626B1 (en) 2020-07-08
JP6868008B2 (ja) 2021-05-12
CN108290890B (zh) 2021-08-06
EP3344628A1 (en) 2018-07-11
US10155762B2 (en) 2018-12-18
JP2018527355A (ja) 2018-09-20
CN108290890A (zh) 2018-07-17
DK3344627T5 (da) 2021-08-30
CN109071540B (zh) 2021-06-04
JP6736660B2 (ja) 2020-08-05
TWI686393B (zh) 2020-03-01
JP6639651B2 (ja) 2020-02-05
TW201716409A (zh) 2017-05-16
CN108349934A (zh) 2018-07-31
IL257732A (en) 2018-04-30
TWI695836B (zh) 2020-06-11
CA2997501A1 (en) 2017-03-09
IL257737A (en) 2018-04-30
TW201722954A (zh) 2017-07-01
US10358448B2 (en) 2019-07-23
JP2018526387A (ja) 2018-09-13
CN108495854B (zh) 2021-10-15
EP3344626B9 (en) 2021-08-11
CA2997545C (en) 2022-01-11
IL257740A (en) 2018-04-30
IL257735A (en) 2018-04-30
DK3344626T3 (da) 2020-07-27
TW201722951A (zh) 2017-07-01
DK3344614T3 (da) 2020-07-27
TW201920176A (zh) 2019-06-01
TWI639597B (zh) 2018-11-01
TWI636054B (zh) 2018-09-21
WO2017040772A1 (en) 2017-03-09
ES2812233T9 (es) 2022-02-18
EP3344628A4 (en) 2019-03-27
DK3344628T3 (da) 2020-08-03
IL257737B2 (en) 2023-02-01
EP3344614A1 (en) 2018-07-11
US20190112311A1 (en) 2019-04-18
TW201811786A (zh) 2018-04-01
EP3344629A4 (en) 2019-03-27
US20170066768A1 (en) 2017-03-09
EP3344614B1 (en) 2020-07-08
WO2017040772A9 (en) 2019-03-07
US20170066770A1 (en) 2017-03-09
ES2812233T3 (es) 2021-03-16
JP2018531907A (ja) 2018-11-01
US20180291024A1 (en) 2018-10-11
TW201722955A (zh) 2017-07-01
EP3344627B1 (en) 2020-07-01
US10040797B2 (en) 2018-08-07
CA2997543A1 (en) 2017-03-09
US10040795B2 (en) 2018-08-07
US10351565B2 (en) 2019-07-16
US10040796B2 (en) 2018-08-07
IL257734A (en) 2018-04-30
EP3344614A4 (en) 2019-03-27
TWI641608B (zh) 2018-11-21
TW201833110A (zh) 2018-09-16
ES2807901T3 (es) 2021-02-24
CN109153679B (zh) 2022-04-08
IL257732B (en) 2020-11-30
TW201835082A (zh) 2018-10-01
TW201819381A (zh) 2018-06-01
DK3344627T3 (da) 2020-07-20
ES2808048T9 (es) 2022-02-01
US20170066767A1 (en) 2017-03-09
EP3344628B9 (en) 2021-06-30
ES2809703T9 (es) 2022-01-24
TWI663167B (zh) 2019-06-21
TWI707854B (zh) 2020-10-21
US20170066769A1 (en) 2017-03-09
IL257734B (en) 2021-07-29
US10766898B2 (en) 2020-09-08
CA2997541C (en) 2022-01-11
US20180327406A1 (en) 2018-11-15
DK3344614T5 (da) 2021-08-30
EP3344627A1 (en) 2018-07-11
EP3344614B9 (en) 2021-07-28
CA2997430C (en) 2021-05-11
ES2807901T9 (es) 2022-01-31
TWI672303B (zh) 2019-09-21
CN108349934B (zh) 2021-10-22
EP3344629A1 (en) 2018-07-11
EP3344628B1 (en) 2020-07-15
US10351566B2 (en) 2019-07-16
TWI654188B (zh) 2019-03-21
CA2997545A1 (en) 2017-03-09
US20170066760A1 (en) 2017-03-09
IL257735B (en) 2022-01-01
CA2997543C (en) 2022-07-19
TW201843153A (zh) 2018-12-16
CN109153679A (zh) 2019-01-04
EP3344626A4 (en) 2019-03-27
WO2017040764A1 (en) 2017-03-09
EP3344627A4 (en) 2019-03-27
CA2997541A1 (en) 2017-03-09
US9994572B2 (en) 2018-06-12
US20180327405A1 (en) 2018-11-15
DK3344628T5 (da) 2021-07-26
IL257737B (en) 2022-10-01
TW201722953A (zh) 2017-07-01
WO2017040767A1 (en) 2017-03-09
WO2017040778A1 (en) 2017-03-09
WO2017040770A1 (en) 2017-03-09
ES2809703T3 (es) 2021-03-05
JP2018527356A (ja) 2018-09-20
EP3344626A1 (en) 2018-07-11
CA2997430A1 (en) 2017-03-09
EP3344627B9 (en) 2021-08-04
JP2018526388A (ja) 2018-09-13
JP6736661B2 (ja) 2020-08-05
JP6736659B2 (ja) 2020-08-05
CN108495854A (zh) 2018-09-04

Similar Documents

Publication Publication Date Title
IL258931A (en) Therapeutic compounds and methods
DK3328880T3 (da) Terapeutiske midler
DK3474804T4 (da) Medicinsk forbinding
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
EP3597258A4 (en) CATHETER ARRANGEMENT
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
EP3628363A4 (en) CATHETER ARRANGEMENT
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte
DK2967049T3 (da) Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme
DK3389669T3 (da) Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf
DK3395801T3 (da) Arylazolforbindelse og skadedyrsbekæmpelsesmiddel
EP3661583A4 (en) CATHETER ARRANGEMENT
ZA201802256B (en) Compounds and therapeutic uses thereof
EP3417902A4 (en) CATHETER ARRANGEMENT
DK3231793T3 (da) Dihydropyromidin-2-on-forbindelser og medicinske anvendelser deraf
MA42266A (fr) Agent thérapeutique contre la fibrose
DK3615502T3 (da) Terapeutiske forbindelser og fremgangsmåder
EP3357532A4 (en) MEDICAL LONG ELEMENT
ZA201801134B (en) Hydroxytriazine compound and medical use thereof
ZA201802134B (en) Therapeutic compounds and methods of use thereof
DK3190116T3 (da) Pyrazolothiazolforbindelse og medicin omfattende denne
EP3340867A4 (en) NONINVASIVE RESCUE MONITORING
DK3263133T3 (da) Pyridinonforbindelse og anvendelse deraf
EP3626198A4 (en) CATHETER KIT
EP3344629A4 (en) THERAPEUTIC COMPOUND FOR PAIN AND SYNTHESIS THEREOF